English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Background   p73 , a structural and functional homolog of  p53 , plays an important role in modulating cell cycle arrest. This study investigated the association between  p73  G4C14‐to‐A4T14 polymorphism and survival outcomes in a Chinese population of advanced non‐small cell lung cancer (NSCLC) patients treated with platinum agents.    Methods  The  p73  G4C14‐to‐A4T14 polymorphism was genotyped using DNA from blood samples of advanced NSCLC patients (642 in the discovery set and 330 in the replication set). The relationship of the  p73  G4C14‐to‐A4T14 polymorphism with clinical outcomes was analyzed.    Results  Compared with the GC/GC genotype, the genotypes containing AT allele (GC/AT + AT/AT genotypes) were associated with significantly prolonged overall survival ( P  = 0.040) in the discovery set and after pooling results from the replication set. Stratification analysis revealed that the association was more pronounced in subjects who were older ( P  = 0.001), male ( P  = 0.007), smokers ( P  = 0.006), had a low Eastern Cooperative Oncology Group performance status ( P  = 0.001), in tumor node metastasis stage IV ( P  = 0.008), and with adenocarcinoma ( P  = 0.002). The objective response rates of patients with GC/AT + AT/AT genotypes were statistically higher than those with the GC/GC genotype ( P  = 0.047).    Conclusion  Our findings suggest that the  p73  G4C14‐to‐A4T14 polymorphism may be related to survival outcome in advanced NSCLC patients.

P73 G4C14‐to‐A4T14 polymorphism is associated with survival in advanced non‐small cell lung cancer patients